News coverage about Nivalis Therapeutics (NASDAQ:ALPN) has trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Nivalis Therapeutics earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.2302652025717 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Several brokerages have recently issued reports on ALPN. Zacks Investment Research lowered Nivalis Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, October 26th. ValuEngine raised Nivalis Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 30th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $7.42.

Nivalis Therapeutics (ALPN) opened at $10.60 on Tuesday. The company has a current ratio of 32.38, a quick ratio of 32.38 and a debt-to-equity ratio of 0.05. Nivalis Therapeutics has a one year low of $7.20 and a one year high of $14.52.

TRADEMARK VIOLATION WARNING: This report was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://theolympiareport.com/2017/12/05/nivalis-therapeutics-alpn-earning-somewhat-favorable-news-coverage-analysis-shows.html.

About Nivalis Therapeutics

Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.

Insider Buying and Selling by Quarter for Nivalis Therapeutics (NASDAQ:ALPN)

Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.